Clinical trials: Patients With Cancer
Advanced Malignant Tumors
Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors
This is Phase 1 study FIH to check "Dose Escalation, Dose expansion and Indication expansion". This study is AUSTRALIA only study.
- Trial name
- NCT05082545
- Testing
- SHR-2002 and SHR-1316
- Where
- 4 sites in Australia
- Volunteers
- 19 people
- Sponsor
- Atridia Pty Ltd.
Colorectal Cancer, CRC
Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer
This is a 2-arm, noncomparative phase 2 trial designed to evaluate treatment outcomes with or without the addition of ciprofloxacin, metronidazole, and aspirin to first-line chemotherapy for patients with stage IV colorectal…
- Trial name
- NCT06728072
- Testing
- Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin
- Where
- 2 sites in United States
- Volunteers
- 97 people
- Sponsor
- Virginia Commonwealth University
Colorectal Adenocarcinoma, Stage I Colorectal Cancer AJCC v8
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread.
- Conditions
- Colorectal Adenocarcinoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8
- Trial name
- NCT04739072
- Testing
- Biospecimen Collection, Electronic Health Record Review
- Where
- 10 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumors
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment, while the majority of patients will eventually…
- Trial name
- NCT01999972
- Testing
- axitinib, crizotinib
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 50 people
- Sponsor
- Pfizer
Colorectal Cancer
A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
This is a Phase II, open label, multicentre, multi-arm, study to evaluate the preliminary efficacy and safety of RXC004 as monotherapy and in combination with nivolumab in patients with Ring finger protein 43 (RNF43) or R-spondin…
- Trial name
- NCT04907539
- Testing
- RXC004, Nivolumab, Denosumab
- Where
- 22 sites in United States, South Korea and 2 more
- Volunteers
- 25 people
- Sponsor
- Redx Pharma Ltd
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)
This study consists of two parts. Phase Ia is a dose escalation study to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of MRG001.
- Trial name
- NCT05155839
- Testing
- MRG001
- Where
- 12 sites in China
- Volunteers
- 108 people
- Sponsor
- Shanghai Miracogen Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Mistletoe Lectin in Treating Patients With Refractory Advanced Solid Tumors
RATIONALE: Mistletoe lectin may slow the growth of cancer cells and be an effective treatment for solid tumors. PURPOSE: Phase I trial to study the effectiveness of mistletoe lectin in treating patients who have refractory…
- Trial name
- NCT00006477
- Testing
- mistletoe extract
- Where
- 2 sites in Germany, Norway
- Volunteers
- 26 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Couple-Focused Intervention for Breast Cancer Patients
The goal of the proposed study is to evaluate the efficacy of 2 couple-focused interventions developed to reduce the psychological distress on women and their partners during and after the breast cancer experience.
- Trial name
- NCT00940277
- Testing
- Group Counseling
- Where
- 5 sites in United States
- Volunteers
- 611 people
- Sponsor
- Fox Chase Cancer Center
Primary Breast Cancer
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer
The primary objective of this trial is to compare the rate of pathologically complete remissions achieved using a preoperative dose-intensified 8 week therapy consisting of adriamycin and docetaxel with a preoperative sequential…
- Trial name
- NCT00793377
- Testing
- Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid
- Where
- Germany
- Volunteers
- 913 people
- Sponsor
- GBG Forschungs GmbH
Low Anterior Resection Syndrome
Paula Method of Exercises in Patients With LARS Syndrome:Randomized Controlled Trial
Sphincter sparing rectal resection surgery, either total mesorectal excision (TME) with a temporary loop ileostomy or partial mesorectal excision (PME), is the mainstay of rectal cancer treatment , however, these treatments are…
- Trial name
- NCT05682157
- Testing
- Paula Method of muscle exercises
- Where
- 2 sites in Israel
- Volunteers
- 62 people
- Sponsor
- Hadassah Medical Organization
Unspecified Childhood Solid Tumor, Protocol Specific
Pharmacokinetics of Daunorubicin in Young Patients With Cancer
This laboratory study is looking at the pharmacokinetics of daunorubicin in young patients with cancer. Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more…
- Trial name
- NCT00673257
- Testing
- pharmacological study, dual x-ray absorptimetry
- Where
- 60 sites in United States, Australia and 2 more
- Volunteers
- 107 people
- Sponsor
- Children's Oncology Group
Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Collection of Blood Samples in Patients With Non-small Cell Lung Cancer
This pilot research trial studies the collection of blood samples in monitoring tumor specific mutations in patients with non-small cell lung cancer that has spread to other places in the body or cannot be removed by surgery.
- Conditions
- Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT03492801
- Testing
- Biospecimen Collection, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Southern California
Brain and Central Nervous System Tumors, Breast Cancer
BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain
RATIONALE: Osmotic blood-brain barrier disruption uses certain drugs, such as mannitol, to open the blood vessels around the brain and allow tumor-killing substances to be carried directly to the brain.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Cognitive/Functional Effects, Drug/Agent Toxicity by Tissue/Organ
- Trial name
- NCT00397501
- Testing
- trastuzumab, carboplatin, methotrexate
- Sponsor
- OHSU Knight Cancer Institute
Glioma
A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas
This study assesses the tolerability, safety, efficacy and pharmacokinetics of RTA 744 in recurrent high-grade gliomas.
- Trial name
- NCT00526812
- Testing
- RTA 744, RTA 744 injection
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- Biogen
Carcinoma, Non-Small-Cell Lung
Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)
Apatinib is a new kind of selective Vascular Endothelial Growth Factor Receptor 2(VEGFR-2) tyrosine kinase inhibitor (TKI). The investigators have finished the preclinical,phase I and phase II clinical studies and found its…
- Trial name
- ANSWER (NCT02332512)
- Testing
- Apatinib
- Where
- 2 sites in China
- Volunteers
- 417 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer, Mastectomy; Lymphedema
Examining the Cosmetic Results, Quality of Life and Patient Satisfaction Achieved With Skin Reducing Nipple Sparing Mastectomy and Implant Based Breast Reconstruction, and Comparing it to Classic Skin- Sparing Mastectomy and Implant- Based Breast Reconstructive Surgeries
This is a response-adaptive (RAR) prospective randomized study with a long-term follow-up and the aim of this clinical study is to measure with qualitative and quantitative indicators the changes in cosmetic results, quality of…
- Conditions
- Breast Cancer, Mastectomy; Lymphedema, Quality of Life, Patient Satisfaction
- Trial name
- NCT04345081
- Testing
- Skin Reducing Nipple Sparing Mastectomy and Implant Based Breast Reconstruction, Skin- Sparing Mastectomy and Implant- Based Breast Reconstructive Surgery
- Where
- Hungary
- Volunteers
- 110 people
- Sponsor
- National Institute of Oncology, Hungary
Head and Neck Cancer
Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies
This is a prospective, multicenter, multi-cohort, Phase II clinical trial enrolling patients with unresectable, recurrent, or metastatic soft tissue sarcoma, malignant melanoma, adenoid cystic carcinoma, or salivary gland…
- Trial name
- NCT07662681
- Testing
- camrelizumab with famitinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Brain and Central Nervous System Tumors, Sarcoma
High-Dose Methotrexate in Treating Young Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as high-dose methotrexate work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00513981
- Testing
- leucovorin calcium, methotrexate, mass spectrometry
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 36 people
- Sponsor
- Children's Cancer and Leukaemia Group
Chronic Lymphocytic Leukemia (CLL), Lymphoma, Non-Hodgkin (NHL)
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
The purpose of this study is to determine the dose that can be safely given to see what effect it may have on your cancer and to determine how the drug is distributed in the body.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Lymphoma, Non-Hodgkin (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
- Trial name
- NCT00710528
- Testing
- CAL-101
- Where
- 9 sites in United States
- Volunteers
- 192 people
- Sponsor
- Gilead Sciences
Malignant Melanoma
4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy
Phase Ib/II open-label, multi-center study with a priming cycle of 4SC-202 to evaluate the safety, tolerability and preliminary efficacy of combination treatment with 4SC-202 and Pembrolizumab.
- Trial name
- SENSITIZE (NCT03278665)
- Testing
- 4SC-202 in combination with Pembrolizumab
- Where
- 7 sites in Germany, Italy
- Volunteers
- 40 people
- Sponsor
- 4SC AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.